As Bilim Pharmaceuticals, we laid down the foundation of our sustainability efforts in 1998. We have been implementing the EFQM (European Foundation for Quality Management) Excellence Model since 1998. In the light of these efforts, we have been measuring our economic, environmental and social impacts and preparing improvement plans to reach our long term dream. We have been implementing the reputation management model since the end of 2006. In this manner, “sustainability” became one of our corporate strategies.

We even have a Board of Sustainability supported by our Company’s CEO, which is comprised of executives from all departments, who have the right to take decision on behalf of our Company. In order to integrate the sustainability approach into all business strategies, the Sustainability Board drafts strategic plans, determines targets and monitors and evaluates practices. By considering the performance indicators of boards and directorships who are effective in Company’s management in junction with their sustainability-related indicators, the Board is able to monitor the performances of the boards and directorships and the developments in this field.

For Bilim Pharmaceuticals, which is a responsible citizen, the priority issues in sustainability are the happiness of people, social development and environmental protection. We seek to develop ourselves in these matters and produce innovative practices, which may be an example for others.

It is our primary target to build our sustainability approach within our corporate culture. On this journey, we attach importance to the participation and development of all our stakeholders, placing priority on our employees, our customers and our suppliers.

Transparency and accountability lie behind our sustainability efforts. By determining the fields that are open to improvement, we find and question the problem in its source before making any improvement plans. It is very important for us that improvement plans are permanent, applicable and able to foster change.

We defined our target as being a pioneer in our own sector and in the Turkish business world by means of our sustainability efforts.

Our Corporate Responsibility Report 2010 is the first report in Turkey to have received Level A approval from the GRI. In 2010, we became the first pharmaceutical company in Turkey to sign the Global Compact. We measure our carbon footprints every year in order to assess our environmental impact and to effect the necessary improvements. We broke further ground in the pharmaceutical industry; we published the sector’s first carbon footprint report in 2010.